• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's After-Market Session

    1/29/24 4:31:25 PM ET
    $ADAP
    $ATPC
    $BFLY
    $CNSP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Nursing Services
    Health Care
    Get the next $ADAP alert in real time by email

    Gainers

    • Agape ATP (NASDAQ:ATPC) stock increased by 39.2% to $0.71 during Monday's after-market session. The company's market cap stands at $54.7 million.
    • CNS Pharma (NASDAQ:CNSP) stock rose 14.52% to $0.38. The company's market cap stands at $2.3 million.
    • Ekso Bionics Holdings (NASDAQ:EKSO) stock increased by 10.22% to $1.94. The market value of their outstanding shares is at $34.5 million.
    • Oncternal Therapeutics (NASDAQ:ONCT) shares increased by 9.56% to $10.93. The company's market cap stands at $32.3 million.
    • NanoVibronix (NASDAQ:NAOV) stock rose 8.21% to $1.05. The company's market cap stands at $2.1 million.
    • Alaunos Therapeutics (NASDAQ:TCRT) stock moved upwards by 7.79% to $0.17. The company's market cap stands at $40.9 million.

    Losers

    • OneMedNet (NASDAQ:ONMD) shares decreased by 12.6% to $1.18 during Monday's after-market session. The company's market cap stands at $38.0 million.
    • Palisade Bio (NASDAQ:PALI) shares declined by 10.95% to $0.85. The market value of their outstanding shares is at $7.9 million.
    • Adaptimmune Therapeutics (NASDAQ:ADAP) stock fell 6.77% to $0.74. The market value of their outstanding shares is at $168.1 million.
    • Butterfly Network (NYSE:BFLY) shares declined by 6.53% to $1.0. The market value of their outstanding shares is at $207.1 million.
    • Soleno Therapeutics (NASDAQ:SLNO) stock declined by 6.11% to $45.06. The company's market cap stands at $1.3 billion.
    • NovaBay Pharmaceuticals (AMEX:NBY) stock decreased by 5.51% to $0.17. The market value of their outstanding shares is at $1.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADAP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADAP
    $ATPC
    $BFLY
    $CNSP

    CompanyDatePrice TargetRatingAnalyst
    Palisade Bio Inc.
    $PALI
    3/26/2026$7.00Buy
    H.C. Wainwright
    Palisade Bio Inc.
    $PALI
    2/25/2026$5.00Buy
    Stifel
    Palisade Bio Inc.
    $PALI
    1/9/2026$7.00Buy
    B. Riley Securities
    Palisade Bio Inc.
    $PALI
    12/29/2025$25.00Overweight
    Piper Sandler
    Soleno Therapeutics Inc.
    $SLNO
    11/18/2025$75.00Outperform
    Wolfe Research
    Soleno Therapeutics Inc.
    $SLNO
    10/7/2025$125.00Buy
    Goldman
    Soleno Therapeutics Inc.
    $SLNO
    8/20/2025$123.00Overweight
    Wells Fargo
    Butterfly Network Inc.
    $BFLY
    8/1/2025Outperform → Perform
    Oppenheimer
    More analyst ratings

    $ADAP
    $ATPC
    $BFLY
    $CNSP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Jones Jason C

    4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

    3/20/26 7:05:29 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    SEC Form 4 filed by Wong Jerome

    4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

    3/20/26 7:03:57 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    President & CEO Devivo Joseph sold $1,788,291 worth of shares (482,149 units at $3.71), decreasing direct ownership by 6% to 8,030,899 units (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    3/6/26 4:05:36 PM ET
    $BFLY
    Medical Electronics
    Health Care

    $ADAP
    $ATPC
    $BFLY
    $CNSP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Palisade Bio with a new price target

    H.C. Wainwright initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $7.00

    3/26/26 8:49:56 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stifel initiated coverage on Palisade Bio with a new price target

    Stifel initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $5.00

    2/25/26 7:53:12 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    B. Riley Securities initiated coverage on Palisade Bio with a new price target

    B. Riley Securities initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $7.00

    1/9/26 9:07:04 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADAP
    $ATPC
    $BFLY
    $CNSP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NovaBay Pharmaceuticals Announces Name Change to Stablecoin Development Corporation, Reports Initial Staking Rewards, and Provides SKY Token Holdings Update

    Following $134 million investment from R01 Fund LP, Framework Ventures, Tether Investments, S.A. de C.V., and Sky Frontier Foundation, Stablecoin Development Corporation has acquired 2.06 billion SKY tokens Key Highlights: Corporate name change from NovaBay Pharmaceuticals, Inc. to Stablecoin Development Corporation; ticker symbol change from NBY to SDEV on the NYSE American, expected to be effective on Friday, April 3, 2026Approximately 2.06 billion SKY tokens held as of March 16, 2026, representing approximately 8.78% of the total supply of SKYApproximately 26.6 million SKY tokens earned in cumulative staking rewards since commencing on-chain staking activitiesApproximately 1.09 billion

    3/23/26 8:30:00 AM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OneMedNet and Navidence Announce Strategic Collaboration: Empowering Pharma with Precision Real-World Data Insights

    MINNEAPOLIS, March 18, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) (the "OneMedNet," the "Company," "we," "us" or "our"), a leading provider of regulatory decision-grade, AI-ready Real-World Data (RWD), today announced a strategic collaboration with Navidence to help research organizations transform rapidly expanding healthcare data into clear, actionable real-world evidence. What This Collaboration Means for the Pharma Market Pharmaceutical companies face growing pressure to integrate high-quality RWD for regulatory submissions, post-market surveillance, and AI model training. Navidence's platform enables precise definition of health data needs via Computable Operationa

    3/18/26 8:50:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Butterfly Network Appoints David Horsley as Senior Vice President, Innovation – Butterfly Embedded™

    Chirp Microsystems Co-Founder Joins Butterfly to Advance its Ultrasound-on-Chip™ Platform Strategy Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced the appointment of David Horsley, Ph.D. as Senior Vice President of Innovation – Butterfly Embedded™ to scale its Ultrasound-on-Chip™ co-development and licensing initiative. In this role, Dr. Horsley will lead strategy and go-to-market for Butterfly Embedded, overseeing new product development, partnerships, and commercialization efforts. Butterfly Embedded is focused on extending the reach of the company's proprietary semic

    3/10/26 8:05:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    $ADAP
    $ATPC
    $BFLY
    $CNSP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Asher Daniel bought $191,162 worth of shares (15,540 units at $12.30) (SEC Form 4)

    4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

    2/20/26 4:57:37 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    Large owner Asher Daniel bought $11,520 worth of shares (1,200 units at $9.60) (SEC Form 4)

    4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

    2/19/26 4:03:47 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    Large owner Asher Daniel bought $970,069 worth of shares (102,029 units at $9.51) (SEC Form 4)

    4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

    2/17/26 3:42:24 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    $ADAP
    $ATPC
    $BFLY
    $CNSP
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Soleno Therapeutics Inc.

    SCHEDULE 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    3/27/26 1:16:59 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Butterfly Network Inc.

    SCHEDULE 13G/A - Butterfly Network, Inc. (0001804176) (Subject)

    3/26/26 4:40:28 PM ET
    $BFLY
    Medical Electronics
    Health Care

    NovaBay Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)

    3/23/26 8:37:01 AM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAP
    $ATPC
    $BFLY
    $CNSP
    Leadership Updates

    Live Leadership Updates

    View All

    Butterfly Network Appoints David Horsley as Senior Vice President, Innovation – Butterfly Embedded™

    Chirp Microsystems Co-Founder Joins Butterfly to Advance its Ultrasound-on-Chip™ Platform Strategy Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly"), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced the appointment of David Horsley, Ph.D. as Senior Vice President of Innovation – Butterfly Embedded™ to scale its Ultrasound-on-Chip™ co-development and licensing initiative. In this role, Dr. Horsley will lead strategy and go-to-market for Butterfly Embedded, overseeing new product development, partnerships, and commercialization efforts. Butterfly Embedded is focused on extending the reach of the company's proprietary semic

    3/10/26 8:05:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer

    REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Jennifer Fulk as Chief Financial Officer, succeeding James Mackaness, who announced that he will be retiring from the Company by the end of the first quarter. Mr. Mackaness will serve as a consultant to Soleno through the end of the year to ensure a smooth transition. Mrs. Fulk brings to Soleno more than two decades of public company experience in leading financial strategy, investor relations, financial reporting, and operational efficiency, with a diverse c

    2/26/26 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

    Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon, today announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board (CAB). Dr. Verstockt is an internationally recognized expert in inflammatory bowel disease (IBD) and a leader in precisi

    2/17/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADAP
    $ATPC
    $BFLY
    $CNSP
    Financials

    Live finance-specific insights

    View All

    Butterfly Network Reports Fourth Quarter 2025 Financial Results

    Delivered Record Annual and Quarterly Revenue Reported quarterly record Revenue of $31.5 million in Q4, representing 41% YoY growth Generated positive net cash flow of $6.3 million in Q4 and lowest annual cash usage in company history Midjourney partnership contributed $6.8 million of revenue in Q4, advancing Butterfly Embedded™ platform strategy Butterfly Network, Inc. (NYSE:BFLY) ("Butterfly" or the "Company"), a digital health company transforming care with semiconductor chip-based ultrasound devices, software and AI, today announced financial results for the fourth quarter and year ended December 31, 2025, and provided a business update. Joseph DeVivo, Butterfly's Presiden

    2/26/26 6:30:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR

    REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2025 and provided an update on the U.S. launch of VYKAT™ XR (diazoxide choline) extended-release tablets. Fourth Quarter and Full-Year 2025 and Recent Corporate Highlights Revenue, net, from the sale of VYKAT XR for the three and twelve months ended December 31, 2025, was $91.7 million and $190.4 million, respectively.From approval on March 26, 2025 through December 31, 2025, Soleno reports: 1,250 patien

    2/25/26 4:01:00 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 4:30 PM ET

    REDWOOD CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its fourth quarter and full-year 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, February 25, 2026. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Wednesday, February 25, 2026Time:4:30 PM Eastern TimeUnited States:1-800-717-1738Internation

    2/11/26 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ADAP
    $ATPC
    $BFLY
    $CNSP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Soleno Therapeutics Inc.

    SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    11/19/24 9:44:27 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by NanoVibronix Inc.

    SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)

    11/14/24 5:17:34 PM ET
    $NAOV
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13D/A filed by Soleno Therapeutics Inc.

    SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    11/14/24 4:30:58 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care